drugset / Trial / NCT02221947
Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease
Phase 1/2
Terminated
9 enrolled
Neurotrope Bioscience, Inc.
Blanchette Rockefeller Neurosciences Insitute · collab
RandomizedSingle-groupQuadruple-blindTreatment
Summary
This study is being done to evaluate the safety, tolerability and potential effectiveness of a new investigational drug, bryostatin 1, in patients with Alzheimer's disease (AD).
Timeline
- Start
- 2014-06
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | bryostatin 1 | Small molecule | 25 ug/m2 | Intravenous |